We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Limping to the finish

18 March 2014 By Robert Cyran

Private equity has reaped good returns from several big LBOs that suffered near-death experiences. So the far healthier Biomet, taken private for $11.4 bln, might seem a natural winner. But a decline in prices for its devices means backers will endure nagging injuries. 

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)